top of page
Anti- PD-L1 (clone QR001)

Anti- PD-L1 (clone QR001)

PD-L1 (CD274, B7-H1) – A Key Marker for Immunotherapy
NordicQC Run C2 & C3 2018 Evaluation ✅ Optimal staining for clone QR001!
The Role of PD-L1 in Immune Regulation
✔ PD-L1 (CD274, B7-H1) is a protein that inhibits T-cell activation and immune response by binding to the PD-1 receptor on cytotoxic T lymphocytes.
✔ Many tumors upregulate PD-L1 expression, leading to T-cell inactivation and allowing the tumor to evade immune surveillance.
✔ Anti-PD-1/PD-L1 therapy restores immune function by blocking this inhibitory pathway, allowing T cells to target and destroy tumor cells.
Clinical Significance of PD-L1 in Cancer
✔ PD-L1 expression assessment in tumor cells helps identify patients who may benefit from PD-1/PD-L1 inhibitor therapy.
✔ PD-L1 is expressed in multiple tumor types, including:
      
  • Non-small cell lung cancer (NSCLC)
    •   
  • Malignant melanoma
    •   
  • Renal cell carcinoma (RCC)
    •   
  • Bladder cancer
    •   
  • Gastric cancer
    •   
  • Colorectal cancer (CRC)
    •   
  • Pancreatic cancer
    •   
  • Triple-negative breast cancer (TNBC)
    •   
  • Classical Hodgkin lymphoma (CHL)
    •   
  • Other malignancies
Anti-PD-L1 (QR001) Antibody – High Sensitivity and Specificity
✔ The rabbit monoclonal anti-PD-L1 antibody (QR001) provides:
      
  • Consistent performance
    •   
  • No cross-reactivity with PD-L2 or other antigens
    •   
  • High specificity and sensitivity, validated in international studies and quality assurance programs
    ✔ Laboratory-developed assays (LDA) using QR001 for PD-L1 status assessment:
    •   
  • Reduce costs by up to 5-fold compared to commercial diagnostic tests
    •   
  • Maintain high-quality results
Summary
✔ PD-L1 is a key predictive marker for cancer immunotherapy.
✔ Its expression is found in multiple cancers, including NSCLC, melanoma, RCC, and TNBC.
✔ QR001 ensures high-quality staining with no PD-L2 cross-reactivity.
✔ IHC-based PD-L1 evaluation enables better patient selection for anti-PD-1/PD-L1 therapy, potentially improving treatment outcomes.

    • [1] Weissinger S et al. (2022). EJHaem. 23;3(3):688-697. Suppl. JHA2-3-688-s005.

      [2] Loghin A et al. (2022). Virchows Arch. 480(2):303-313.

      [3] Darmon-Novello M et al. (2022). Histopathology. 80(7):1091-1101.

      [4] Karabajakian A et al. (2021). Oral Oncol. 119:105368.

      [5] Lang-Schwarz C et al. (2021). Int J Colorectal Dis. 36(11):2497-2510.

      [6] Eymerit-Morin C et al. (2021). Eur J Histochem. 65(1):3185.

      [7] Annibali et al. (2021). Sci Rep. 11(1):7059.

      [8] Brandone N et al. (2020). Appl Immunohistochem Mol Morphol. 28(1):23-29.

      [9] Lantuejoul S et al. (2019). J Thorac Dis.11(Suppl 1): 89-101.

      [10] Scimeca M et al. (2019). Urol Oncol. 37(5):297.e19-297.e31.

    • ADVANTAGES OF RECOMBINANT RABBIT MONOCLONAL ANTIBODIES

      Recombinant rabbit monoclonal antibodies—referred to as Q-clones—combine the best properties of both murine monoclonal and rabbit polyclonal antibodies, offering a broader diagnostic potential.

      Key Advantages of Our Next-Generation Recombinant Rabbit Monoclonal Antibodies

      ✔ High Affinity due to rabbit origin, enabling greater sensitivity in assays—these antibodies bind strongly to antigens and maintain their bond even under challenging conditions, unlike low-affinity antibodies.

      ✔ Superior Specificity with reduced risk of cross-reactivity, thanks to their monoclonal nature.

      ✔ Expanded Antigen Recognition—better recognition of diverse antigens and epitopes.

      ✔ Target Epitopes Poorly Recognized by Mouse-Derived Antibodies, improving detection in certain applications.

      ✔ Enhanced Response to Small-Sized Epitopes, making them ideal for challenging targets.

      ✔ Significantly Improved Recognition of Murine Antigens, broadening their usability in research and diagnostics.

      ✔ Lower Background Staining, ensuring cleaner and more reliable results.

      Recombinant vs. Hybridoma Antibody Generation

      ✔ Exceptional Consistency, Specificity, and Sensitivity—eliminating risks of gene loss, mutations, or cell line drift.

      ✔ Reliable and Controlled Production—generated from a unique gene set, ensuring stable antibody performance.

      ✔ Batch-to-Batch Consistency, guaranteeing reproducible results and long-term product availability.

      ✔ Efficient In Vitro High-Throughput Production, allowing easy standardization and scalable antibody expression for any application.

      Recombinant rabbit monoclonal antibodies represent the future of immunohistochemistry, offering unmatched reliability and precision in diagnostic and research settings.

    bottom of page